Rafael C. Rosell
Expertise in
13
conditions

Rafael C. Rosell

Badalona, CT, ES 
Expertise in
13
conditions
Badalona, CT, ES 
OverviewLocationsClinical Research

Overview

Rafael Rosell practices in Badalona, Spain. Mr. Rosell is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Tissue Biopsy, and Adenoidectomy.

His clinical research consists of co-authoring 426 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Badalona, CT, Spain
Other Locations
Oncology Institute Dr. Rosell, Barcelona, CT, Spain
Cerdanyola Del Valles, CT, Spain
Frias, CL, Spain
Bellaterra, CT, Spain
Department Of Otorhinolaryngology Head And Neck Surgery, Sabadell, CT, Spain
Instituto Oncológico Dr Rosell, 1. 08195 Sant Cugat Del Vallès, Sant Cugat Del Valles, CT 08195, Spain
A Coruna, GA, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drugs: Aldoxorubicin, Topotecan
Study Phase: Phase 2

425 Total Publications

Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Journal: Nature communications
Published: December 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rosell's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile